Lineage Cell Therapeutics, Inc.
AMEX:LCTX · New York Stock Exchange American
-$0.04 today
Vol 0.85M · Avg 1.19M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
AMEX:LCTX · Revenue to Net Income
Key Ratios
Analysis
$14.8M of revenue converted into -$64.2M of net income for the selected period. Gross margin is 96.6% and net margin is -544.2%, showing how much revenue survives after costs and taxes. EPS is $-0.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M +53.2% | $9.5M +6.2% | $8.9M -39.2% | $14.7M +277.4% | $3.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $845.0K +153.0% | $334.0K -50.2% | $671.0K -7.8% | $728.0K -48.9% | $1.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.7M +49.6% | $9.2M +10.8% | $8.3M -40.8% | $14.0M +465.8% | $2.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.2% -2.3pp | 96.5% +4.0pp | 92.5% -2.6pp | 95.0% +31.7pp | 63.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.7M +42.2% | $12.5M -20.6% | $15.7M +12.3% | $14.0M -58.8% | $33.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $18.5M +1.6% | $18.2M +5.0% | $17.3M -23.1% | $22.5M +23.6% | $18.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $35.5M +15.8% | $30.6M -7.2% | $33.0M -9.6% | $36.5M -29.4% | $51.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $699.0K +14.8% | $609.0K -12.0% | $692.0K -4.8% | $727.0K -16.7% | $873.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$67.9M -278.1% | -$18.0M +20.4% | -$22.6M +9.9% | -$25.1M +40.8% | -$42.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -466.8% -277.6pp | -189.2% +63.3pp | -252.5% -81.9pp | -170.6% +917.6pp | -1088.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$21.8M -1.4% | -$21.5M +13.2% | -$24.7M -9.8% | -$22.5M +54.2% | -$49.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -149.6% +76.5pp | -226.1% +50.4pp | -276.5% -123.3pp | -153.2% +1109.9pp | -1263.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.7M -1.4% | $1.7M +5.3% | $1.6M +96.5% | $829.0K +41350.0% | $2.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$46.9M -1718.4% | $2.9M +99.6% | $1.5M +144.1% | -$3.3M -155.4% | $5.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$68.6M -269.4% | -$18.6M +20.2% | -$23.3M +9.8% | -$25.8M +40.3% | -$43.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -471.6% -276.0pp | -195.6% +64.7pp | -260.3% -84.7pp | -175.6% +935.1pp | -1110.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$5.1M | $0 +100.0% | -$1.8M -433.3% | $541.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$63.5M -241.4% | -$18.6M +13.4% | -$21.5M +18.2% | -$26.3M +38.9% | -$43.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -436.5% -240.6pp | -195.9% +44.3pp | -240.2% -61.5pp | -178.7% +925.5pp | -1104.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -201.1% | -$0 +22.5% | -$0 +20.0% | -$0 +42.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -201.1% | -$0 +22.5% | -$0 +20.0% | -$0 +42.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $230.1M +14.9% | $200.2M +15.9% | $172.7M +1.7% | $169.8M +3.2% | $164.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $230.1M +14.9% | $200.2M +15.9% | $172.7M +1.7% | $169.8M +3.2% | $164.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$748.36M
Neurogene Inc.
NASDAQ:NGNE
$500.92M
Ocugen, Inc.
NASDAQ:OCGN
$426.54M
PureTech Health plc
NASDAQ:PRTC
$421.39M
Autolus Therapeutics plc
NASDAQ:AUTL
$412.12M
Benitec Biopharma Inc.
NASDAQ:BNTC
$318.11M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$195.88M
Galectin Therapeutics Inc.
NASDAQ:GALT
$184.16M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LCTX generate?
Lineage Cell Therapeutics, Inc. (LCTX) reported $14.56M of revenue in fiscal 2025.
Is LCTX profitable?
Lineage Cell Therapeutics, Inc. (LCTX) reported -$63,533,000.00 of net income, with a net margin of -436.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.